Combined p-tau217 + p-tau231 Panel Increases Specificity for Treatment Cessation Determination

Target: NA - Multi-biomarker diagnostic Composite Score: 0.546 Price: $0.50 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation⚠ Orphaned Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.546
Top 66% of 1374 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.58 Top 63%
C Evidence Strength 15% 0.48 Top 73%
B+ Novelty 12% 0.70 Top 47%
C+ Feasibility 12% 0.50 Top 62%
B Impact 12% 0.60 Top 62%
C Druggability 10% 0.40 Top 77%
B Safety Profile 8% 0.60 Top 36%
B Competition 6% 0.65 Top 53%
C+ Data Availability 5% 0.55 Top 60%
C+ Reproducibility 5% 0.50 Top 67%
Evidence
2 supporting | 2 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

p-tau231 reflects earlier amyloid-driven changes in entorhinal cortex while p-tau217 reflects downstream neuronal involvement. The combination captures the full spectrum of amyloid-to-tau propagation resolution. However, the composite algorithm is not operationally defined, weighting schemes are unspecified, and temporal window evidence from natural disease course may not transfer to treatment kinetics. Addition of p-tau231 may increase assay complexity without proportional predictive gain.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.58 (15%) Evidence 0.48 (15%) Novelty 0.70 (12%) Feasibility 0.50 (12%) Impact 0.60 (12%) Druggability 0.40 (10%) Safety 0.60 (8%) Competition 0.65 (6%) Data Avail. 0.55 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.546 composite
4 citations 4 with PMID Validation: 0% 2 supporting / 2 opposing
For (2)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
MECH 3CLIN 1GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
p-tau231 increases earlier in Alzheimer's cou…SupportingMECH----PMID:37266949-
Combination of plasma p-tau217/p-tau231 ratio impr…SupportingMECH----PMID:36566449-
Combination improves amyloid status discrimination…OpposingCLIN----PMID:36566449-
p-tau231 may be more confounded by non-AD amyloid …OpposingMECH----PMID:NA-
Legacy Card View — expandable citation cards

Supporting Evidence 2

p-tau231 increases earlier in Alzheimer's course than p-tau217
Combination of plasma p-tau217/p-tau231 ratio improves discrimination of amyloid status

Opposing Evidence 2

Combination improves amyloid status discrimination, not treatment cessation outcomes
p-tau231 may be more confounded by non-AD amyloid pathology (CAA, LBD)
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (3)

Metal Ion-Induced Porous MXene for All-Solid-State Flexible Supercapacitors.
Nano letters (2023) · PMID:36566449
No extracted figures yet
Normothermic Regional Perfusion-The Next Frontier in Organ Transplants?
JAMA (2023) · PMID:37266949
No extracted figures yet
Paper:NA
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 NA — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for NA structures...
Querying Protein Data Bank API

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)